↓ Skip to main content

Cochrane Database of Systematic Reviews

Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis

Overview of attention for article published in Cochrane database of systematic reviews, April 1998
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (56th percentile)

Mentioned by

2 Wikipedia pages


51 Dimensions

Readers on

61 Mendeley
Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis
Published in
Cochrane database of systematic reviews, April 1998
DOI 10.1002/14651858.cd000954
Pubmed ID

Janet Pope, D Fenlon, A Thompson, Beverley Shea, Dan Furst, George A Wells, Alan Silman


To assess the effects and toxicity of the following agent: ketanserin versus placebo proposed for the treatment of Raynaud's phenomenon (RP) in scleroderma. We searched the Cochrane Controlled Trials Register, and Medline up to 1996 using the Cochrane Collaboration search strategy developed by Dickersin et al.(1994). Key words included: Raynaud's or vasospasm, scleroderma or progressive systematic sclerosis or connective tissue disease or autoimmune disease. Current Contents were searched up to and including April 7, 1997. All bibliographies of articles retrieved were searched and key experts in the area were contacted for additional and unpublished data. The initial search strategy included all languages. All randomized controlled trials comparing ketanserin versus placebo were eligible if they reported clinical outcomes of interest. Trials with dropout rates greater than 35% were excluded. Data were abstracted independently by two reviewers (DF, AT). Peto's odds ratios (OR) were calculated for all dichotomous outcomes, and a weighted mean difference (WMD) was carried out on all continuous outcomes. A fixed effects or random effects model were used if the data was homogeneous or heterogeneous, respectively. Three trials and 66 patients were included. The proportion improved was significantly better in the group on ketanserin with an odds ratio (OR) of 4.80 (95% CI 1.33, 17.37). However, when comparing ketanserin to placebo, the decrease in severity of RP attacks favoured placebo but this was not statistically significant. Side effects were significantly more common in the group using active treatment with an OR of 5.96 (95% CI 1.61, 22.06). Frequency of attacks did not change, but the duration of attacks decreased significantly in the ketanserin group. Ketanserin may have some efficacy in the treatment of Raynaud's phenomenon secondary to scleroderma. Overall, ketanserin is not significantly different from placebo for the treatment of Raynaud's phenomenon except for some decrease in the duration of attacks and more subjects improved on ketanserin compared to placebo. However, there were more side effects. It can be concluded that ketanserin treatment in Raynaud's phenomenon secondary to scleroderma is not clinically beneficial.

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 60 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 18%
Student > Master 8 13%
Student > Bachelor 7 11%
Other 7 11%
Student > Ph. D. Student 6 10%
Other 8 13%
Unknown 14 23%
Readers by discipline Count As %
Medicine and Dentistry 27 44%
Nursing and Health Professions 4 7%
Biochemistry, Genetics and Molecular Biology 2 3%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Agricultural and Biological Sciences 2 3%
Other 7 11%
Unknown 17 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 December 2020.
All research outputs
of 19,770,032 outputs
Outputs from Cochrane database of systematic reviews
of 11,955 outputs
Outputs of similar age
of 291,459 outputs
Outputs of similar age from Cochrane database of systematic reviews
of 180 outputs
Altmetric has tracked 19,770,032 research outputs across all sources so far. This one is in the 45th percentile – i.e., 45% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,955 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.7. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,459 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 180 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.